Antibody-Based Therapy Eliminates Circulating Tumor Cells in Mouse Models of Breast and Pancreatic Cancer

BOSTON – Investigators have designed an antibody-based treatment that eliminated circulating tumor cells (CTCs) in mouse models of breast and pancreatic cancer. The research, which was led by scientists at Massachusetts General Hospital (MGH) and is published in PNAS, represents a promising strategy to halt the spread of cancer.

To develop antibody-based therapies that can destroy cancer cells, researchers must identify cell surface proteins that distinguish cancer cells from surrounding normal cells. In contrast to tumor cells that arise in a particular organ or tissue, CTCs that are spreading, or metastasizing, through the blood are in an environment of cells that are much different than they are, which expands the number of targetable proteins for scientists to identify. Investigators found that cadherins—transmembrane proteins that normally mediate cell–cell adhesion—are great candidates in this case.

An antibody (called 23C6) against cadherins effectively suppressed blood-borne metastasis in mouse models of pancreatic and triple negative breast cancers. The 23C6 antibody recognizes two different cadherins that are commonly expressed on different types of CTCs. Despite its efficacy against single cells in circulation, the antibody does not suppress the formation of tumors, nor does it elicit detectable toxicity in normal organs, where cadherins may be located within structures connecting cells and hence are inaccessible for antibody binding.

“This therapy may be more effective at targeting CTCs because these antibodies have better access to the circulating cells traveling in the bloodstream and are highly specific to CTCs compared with surrounding blood cells,” says co-author David T. Ting, MD, Associate Clinical Director for Innovation at the MGH Cancer Center and an Associate Professor of Medicine at Harvard Medical School.

The research raises the possibility of developing antibody-based therapies to target CTCs to suppress blood-borne metastasis, which is the predominant cause of cancer mortality. “While metastasis is the major source of lethality in solid tumors, there are no currently approved therapies that specifically target the metastatic process or the subset of invasive cells responsible for cancer spread,” says Ting. “The results suggest that our approach could be effective at targeting diverse types of CTCs. With more research and development, therapies that use this approach could be used to prevent cancers from spreading and improve long term survival.”

Additional co-authors include Douglas S. Micalizzi, Dante Che, Benjamin T. Nicholson, Jon F. Edd, Niyati Desai, Evan R. Lang, Michael B. Brenner, Mehmet Toner, Shyamala Maheswaran, and Daniel A. Haber.

This work was supported by the National Institutes of Health, the Breast Cancer Research Foundation, the Howard Hughes Medical Institute, and National Foundation for Cancer Research, ESSCO Breast Cancer Research Fund, American Cancer Society, and the Terri Brodeur Breast Cancer Foundation.

Paper Cited:

Micalizzi, D. S., Che, D., Nicholson, B. T., Edd, J. F., Desai, N., Lang, E. R., Toner, M., Maheswaran, S., Ting, D. T., & Haber, D. A. (2022). Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody. Proceedings of the National Academy of Sciences of the United States of America, 119(43), e2209563119. https://doi.org/10.1073/pnas.2209563119

About the Massachusetts General Hospital

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In July 2022, Mass General was named #8 in the U.S. News & World Report list of "America’s Best Hospitals."